前列腺是临床上重要的男性附属生殖腺，对精液生成至关重要。前列腺癌（PCa）目前在香港男性癌症年发病率中排名第三，在男性癌症相关死亡中排名第五，每 100,000 人中约有 10.9 人死亡。其发病率正迅速上升，过去 10 年几乎增加了两倍。
适应症：Prostate Cancer
入组条件
纳入标准
- All new, consecutive patients with histological proven prostate cancer or clinically diagnosed to have prostate cancer, who decided for ADT would be recruited for the study
排除标准
- Prior neoadjuvant or adjuvant hormone therapy within 1 year before
- Refuse or unable to give written informed consent
- Participation in an investigational program with interventions outside of routine clinical practice
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年11月5日。